Abstract #0486

Neurometabolic changes in RRMS: comparison between fingolimod and injectables therapies

Oun Al-iedani^1,2, Saadallah Ramadan^2,3, Karen Ribbons², Rodney Lea², and Jeannette Lechner-Scott^2,4,5

¹School of Health Sciences, University of Newcastle, Newcastle, Australia, ²Hunter Medical Research Institute, Newcastle, Australia, ³Faculty of Health and Medicine, University of Newcastle, Newcastle, Australia, ⁴Department of Neurology, John Hunter Hospital, Newcastle, Australia, ⁵School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

This novel study compares the neurometabolic effects of different DMTs on the MS brain. We evaluated volumetric and neurometabolic changes in RRMS patients on fingolimod(N=52), injectables(N=46) and HCs cohort(N=51). MRS was acquired from PCG and PFC. Compared to HCs, a significant reduction in NAA/tCr were detected in both locations and cohorts. Clinical parameters, MR-volumetrics and neurometabolic concentrations showed no statistically significant differences between RRMS cohorts. MRI metrics and neurometabolites from both locations, showed moderate correlations with cognition, fatigue and memory. This the first study demonstrating that fingolimod and injectable DMTs influence volumetric and neurometabolic profiles of MS-brain similarly.

This abstract and the presentation materials are available to members only; a login is required.

Join Here